123 related articles for article (PubMed ID: 9241551)
1. Raised prostate-specific antigen in adenocarcinoma of the colon.
Yamamoto M; Hibi H; Miyake K
Int Urol Nephrol; 1997; 29(2):221-5. PubMed ID: 9241551
[TBL] [Abstract][Full Text] [Related]
2. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer.
Kwak C; Ku JH; Kim T; Park DW; Choi KY; Lee E; Lee SE; Lee C
Urology; 2003 Nov; 62(5):854-9. PubMed ID: 14624908
[TBL] [Abstract][Full Text] [Related]
3. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
5. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M
Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study.
Farrelly C; Lal P; Trerotola SO; Nadolski GJ; Watts MM; Gorrian CM; Guzzo TJ
Cardiovasc Intervent Radiol; 2016 May; 39(5):724-731. PubMed ID: 26957011
[TBL] [Abstract][Full Text] [Related]
8. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
9. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
10. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
12. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
Bruwer G; Heyns CF; Allen FJ
Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
[TBL] [Abstract][Full Text] [Related]
13. Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies.
Vijayakumar S; Quadri SF; Sen S; Vaida F; Ignacio L; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):189-95. PubMed ID: 7536721
[TBL] [Abstract][Full Text] [Related]
14. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
15. Recurrent prostate cancer despite undetectable prostate specific antigen.
Takayama TK; Krieger JN; True LD; Lange PH
J Urol; 1992 Nov; 148(5):1541-2. PubMed ID: 1279216
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
17. [Proper use of prostate specific antigen].
Barthélémy Y; Chopin D; Abbou CC
Rev Prat; 1994 Mar; 44(5):617-9. PubMed ID: 7520597
[TBL] [Abstract][Full Text] [Related]
18. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
Iwakiri J; Granbois K; Wehner N; Graves HC; Stamey T
J Urol; 1993 Apr; 149(4):783-6. PubMed ID: 7681118
[TBL] [Abstract][Full Text] [Related]
19. Saturation biopsy technique increase the capacity to diagnose adenocarcinoma of prostate in patients with PSA < 10 ng/ml, after a first negative biopsy.
Giulianelli R; Brunori S; Gentile BC; Vincenti G; Nardoni S; Pisanti F; Shestani T; Mavilla L; Albanesi L; Attisani F; Mirabile G; Schettini M
Arch Ital Urol Androl; 2011 Sep; 83(3):154-9. PubMed ID: 22184840
[TBL] [Abstract][Full Text] [Related]
20. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
Terris MK; Stamey TA
Br J Urol; 1994 Jan; 73(1):61-4. PubMed ID: 7507783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
